University Of Heidelberg Medical Center

This phase 3 trial tests whether adding the drug isatuximab to standard treatment helps people with newly diagnosed multiple myeloma achieve deeper remission and live longer without the cancer progressing. About 662 participants will receive either standard therapy or standard th…